Company profile for Mindset Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Mindset Pharma is a drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Founded by serial entrepreneurs and domain experts in drug development and medicinal chemistry and based in Toronto, Canada, Mindset is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychia...
Mindset Pharma is a drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Founded by serial entrepreneurs and domain experts in drug development and medicinal chemistry and based in Toronto, Canada, Mindset is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychiatric disorders efficiently and safely.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
217 Queen Street West, 401, Toronto, Ontario M5V 0R2, CA
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospectrumasia.com/news/25/22966/japanese-pharma-firm-otsuka-buys-mindset-pharma-for-cad-80-m-to-strengthen-pipeline-in-neurological-disorders.html

BIOSPECTRUM ASIA
04 Sep 2023

https://www.biospace.com/article/releases/otsuka-pharmaceutical-to-acquire-mindset-pharma/?s=61

BIOSPACE
01 Sep 2023
UK trial to test psilocin-based drug for major depressive disorder
UK trial to test psilocin-based drug for major depressive disorder

28 Jun 2023

// Catherine Eckford EUROPEAN PHARMACEUTICAL REVIEW

https://www.europeanpharmaceuticalreview.com/news/184038/uk-trial-to-test-psilocin-based-drug-for-major-depressive-disorder/

Catherine Eckford EUROPEAN PHARMACEUTICAL REVIEW
28 Jun 2023

https://www.globenewswire.com/news-release/2023/04/26/2654867/0/en/Mindset-Pharma-Files-Two-Patent-Applications-for-its-Non-Hallucinogenic-Non-Tryptamine-Compounds.html

GLOBENEWSWIRE
26 Apr 2023

https://www.globenewswire.com/news-release/2023/04/03/2639404/0/en/Mindset-Pharma-to-Participate-in-the-Sequire-Cannabis-Psychedelics-Conference-on-Wednesday-April-5-2023.html

GLOBENEWSWIRE
03 Apr 2023

https://www.globenewswire.com/news-release/2023/03/28/2635529/0/en/Mindset-Pharma-CEO-James-Lanthier-Issues-Letter-to-Shareholders-Discussing-Expansion-of-Drug-Discovery-Efforts-into-Novel-Non-Hallucinogenic-Therapeutics.html

GLOBENEWSWIRE
28 Mar 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty